Two graduates of the AACR Scientist↔Survivor Program share tips for getting the most out of large scientific conferences.
AACR’s Scientist↔Survivor Program marks a milestone as patient advocates continue to shape research and policy.
In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
Cancer researchers and patient advocates spoke about progress against cancer at a public education forum sponsored by the American Association for Cancer Research.
A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non–small cell lung cancer treatment.
At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors’ molecular characteristics, not to their tissues of origin.
At the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.
Panel of experts discuss survivorship challenges and potential areas for study.
The Biden Cancer Initiative Colloquium gathered experts to discuss obstacles preventing access to care at the AACR Annual Meeting.
National Cancer Institute director Norman “Ned” Sharpless meets with advocates and outlines areas of focus for the agency.
Advocates shared their stories and projects at the AACR Annual Meeting.
In a session at the AACR Annual Meeting, oncologists discussed the state of cancer precision medicine—and engaged with patient advocates.
Cancer Today magazine is free to cancer patients, survivors and caregivers who live in the U.S. Subscribe here to receive four issues per year.